SynthesisOncotarget2017
Quantitative assessment of the diagnostic role of FHIT promoter methylation in non-small cell lung cancer.
Synthesis in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 1 synthesis or guideline pooled it, 14 citations in OpenAlex.
- Meta-analysis and dose-response analysis of low-temperature stress effects on rice yield and physiological responses.Frontiers in plant science · 2026Pooled it
- Review
- Tumor Suppressor 4.1N/Frontiers in genetics · 2022Article
- A transdisciplinary approach to understand the epigenetic basis of race/ethnicity health disparities.Epigenomics · 2021Article
- DNA Methylation Change Profiling of Colorectal Disease: Screening towards Clinical Use.Life (Basel, Switzerland) · 2021Review
- FHIT as a biomarker for early screening of adult T-cell leukemia.Journal of cancer biology · 2021Article
- Genome-Wide Analysis of the DNA Methylation Profile Identifies the Fragile Histidine Triad (Journal of clinical medicine · 2020Article
- Folate deficiency and aberrant DNA methylation and expression of FHIT gene were associated with cervical pathogenesis.Oncology letters · 2018Article
- Methyltransferase G9a promotes cervical cancer angiogenesis and decreases patient survival.Oncotarget · 2017Article
- Association of FHIT expression andOncoTargets and therapy · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aberrant methylation of CpG islands acquired in promoter regions plays an important role in carcinogenesis. Accumulated evidence demonstrates FHIT gene promoter hyper-methylation is involved in non-small cell lung cancer (NSCLC). To test the diagnostic ability of FHIT methylation status on NSCLC, thirteen studies, including 2,119 samples were included in our meta-analysis. Simultaneously, four independent DNA methylation datasets from TCGA and GEO database were analyzed for validation. The pooled odds ratio of FHIT promoter methylation in cancer samples was 3.43 (95% CI: 1.85 to 6.36) compared with that in controls. In subgroup analysis, significant difference of FHIT gene promoter methylation status in NSCLC and controls was found in Asians but not in Caucasian population. In validation stage, 950 Caucasian samples, including 126 paired samples from TCGA, 568 cancer tissues and 256 normal controls from GEO database were analyzed, and all 8 CpG sites near the promoter region of FHIT gene were not significantly differentially methylated. Thus the diagnostic role of FHIT gene in the lung cancer may be relatively limited in the Caucasian population but useful in the Asians.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.